Elicio Therapeutics' KRAS Vaccine Fails Phase 2 Trial, Stock Plunges 73%
Elicio Therapeutics
Developer of Novel Immunotherapy
Therapeutics
For investors in Elicio Therapeutics (NASDAQ: ELTX), June 15 was an unmitigated “Black Monday.”
Elicio Therapeutics Announces Latest Data from the Phase 2 AMPLIFY-7P Clinical Trial of ELI-002 7P, a KRAS Vaccine for Adjuvant Treatment of Pancreatic CancerThe study did not meet the primary endpoint of DFS。
The capital market's reaction was swift and brutal.
The stock price plummeted by over 70% in pre-market trading, falling to around $4 at the open, with its market capitalization shrinking by nearly three-quarters.
For a biotech company that reported a net loss of nearly $40 million in 2025 and has cash runway only until the fourth quarter, this blow is almost fatal.
The “Beauty” of Scientific Logic and the “Cruelty” of Reality
Part.1
ELI-002 7P is an ingeniously designed therapeutic vaccine targeting the seven most common KRAS mutations—mutations carried by approximately 90% of pancreatic cancer patients.
It is designed to activate mKRAS-specific T cells postoperatively, eliminate minimal residual disease, and reduce the high recurrence rate of pancreatic ductal adenocarcinoma (PDAC), the “king of cancers.”
AMPLIFY-7P enrolled 144 postoperative patients to evaluate the adjuvant efficacy of the vaccine in addition to standard care.
However, the results were marred by an “unexpected imbalance” in trial design: the proportion of patients with R1 resection (positive margins, associated with a very poor prognosis) was 19% in the treatment group versus only 10% in the control group. This inherent inequity rendered the analysis of the overall population inherently challenging.
Ultimately,Primary Endpoint DFS Fails to Reverse; Stock Price Plummets。
Glimmer in the Cracks: R0 Subgroup and T Cell Response
Part.2
Yet science often reveals opportunities in the most desperate situations. Post-hoc analysis focused on patients with complete R0 resection—this subgroup accounted for 84% of the enrolled population and had balanced baseline characteristics.
Data showed that the median DFS in the vaccine group reached 23.8 months, nearly double the 12.8 months observed in the control group, with a hazard ratio (HR) of 0.65 (p=0.048) and a 9.5% reduction in the 18-month recurrence rate. More importantly, mKRAS-specific T-cell responses were significantly associated with improved DFS (HR 0.22, p<0.0001), clearly validating biological activity.
The Company immediately announced a strategic adjustment, focusing on the R0 population to advance the optimized Phase 3 clinical trial and adding dosing regimens.
But ideals are full, while reality is lean—Current funds will only last until the fourth quarter, while the substantial investment required for the Phase III trial remains unresolved.。
In the treacherous arena of pancreatic cancer, a single failure can cause market capitalization to collapse. For Elicio, the pressing question is not “whether it can make a comeback,” but “whether it can survive long enough to see that comeback.”
